Articles related to ADJUVANT TREATMENT

Adjuvant durvalumab therapy led to a median overall survival of 55.9 months compared to 33.4 months with placebo in patients with limited-stage small-cell lung cancer who did not progress after chemoradiotherapy.

Experts note that the use of chemotherapy can indicate cancer spread beyond its origin, potentially reflecting the stage, aggressiveness, or progression potential of the disease.

With nearly ten years of follow-up, dabrafenib plus trametinib demonstrates a sustained improvement in survival outcomes for patients with stage III BRAF V600–mutated melanoma, presenting a viable long-term strategy in melanoma management.

In the realm of HER2-positive early breast cancer, achieving a pathological complete response (pCR) post-neoadjuvant therapy has been linked to a markedly reduced risk of recurrence, highlighting the critical role of tailored treatment strategies in improving patient outcomes.

Pembrolizumab now represents a transformative advancement in the adjuvant treatment of clear cell renal cell carcinoma, significantly reducing the risk of progression or death by 38% compared to placebo.

Highlighting a paradigm shift in breast cancer treatment, the NRG Oncology/NSABP B-51/RTOG 1304 study demonstrates that certain patients with node-negative breast cancer post-neoadjuvant chemotherapy may safely omit adjuvant regional nodal irradiation, challenging conventional treatment approaches and potentially improving patient quality of life.